Edition:
India

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.92USD
20 Apr 2018
Change (% chg)

$0.31 (+3.60%)
Prev Close
$8.61
Open
$8.60
Day's High
$8.92
Day's Low
$8.56
Volume
215,424
Avg. Vol
329,801
52-wk High
$34.45
52-wk Low
$6.99

Select another date:

Mon, Mar 5 2018

Dermira to abandon acne drug, shares crater

Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.

Dermira abandons acne drug

March 5 Dermira Inc said on Monday it would discontinue the development of its acne drug after it failed to meet the main goals of two late-stage studies.

BRIEF-Dermira's Two Phase 3 Trials Evaluating Olumacostat Glasaretil In Patients With Acne Vulgaris Did Not Meet Co-Primary Endpoints

* DERMIRA’S TWO PHASE 3 TRIALS EVALUATING OLUMACOSTAT GLASARETIL IN PATIENTS WITH ACNE VULGARIS DID NOT MEET CO-PRIMARY ENDPOINTS

BRIEF-Dermira Qtrly Loss Per Share $‍1.34​

* DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

Select another date: